Hims & Hers Health shares fell about 5% in Tuesday premarket trading after the telehealth company reported a wider-than-expected second-quarter loss and said margins would remain below historical levels as branded GLP-1 weight-loss drugs and international expansion lift costs. Revenue rose to $753.21 million from $544.83 million, beating estimates near $700 million, while subscribers increased 19% to nearly 2.9 million and monthly online revenue per average subscriber climbed 21% to $92. The earnings figures in available reports are inconsistent: Reuters described a 37-cent-per-share loss versus expectations for a 1-cent loss, a later market report said consensus called for a 3-cent loss, and an earlier record cited a 10-cent EPS loss against an expected 5-cent loss. Hims raised full-year revenue guidance to $3.1 billion-$3.3 billion from $2.8 billion-$3 billion, including the Eucalyptus acquisition, and said it still expects to return to profitability in 2027 and reach $6.5 billion in revenue by 2030. Needham maintained a Buy rating and lifted its price target to $42 after the results.